Halozyme Corp (HALO): Price-to-Projected Revenue Ratio

Official company branding of Halozyme (HALO)

Halozyme Therapeutics (HALO) is a reputable developer of drug delivery systems with an impeccable scientific standing. The forward P/S metric illustrates the business valuation trend, where the 2.60 mark characterizes this parameter. However, revenues rely on a narrow circle of partners, creating a risk of declining royalties. Meanwhile, unique patents ensure exceptional pricing power by converting injections into a subcutaneous format.

HALO Halozyme Therapeutics, Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/17/2026

HALO (halozyme.com): analytical breakdowns and indicator data

Analysis of all company metrics:halozyme.com HALO
Manufactured products of Halozyme Therapeutics

Halozyme Therapeutics (HALO) maintains a dominant position by monetizing unique drug delivery methods through a system of long-term royalties. The forward P/S ratio assesses the market value of every dollar of projected revenue, allowing investors to determine the extent of overpayment for expected cash flows. This chart's price action reveals that the asset is overheated, signaling a risk of correction if market expectations outpace the actual growth rate of licensing fees.

Competitor analysis

Forward P/S Multiple ONC (BeiGene Oncology)|Revolution Medicines (RVMD) - Market Cap to Future Revenue Ratio|ascentage.com - Forward P/S Multiple|Forward Price to Sales CGON (cgoncology.com)|URGN: Forward P/S Multiple|Bicara Therapeutics Inc (BCAX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio personalis.com|Forward Price-to-Revenue Multiple Erasca Corp (ERAS)|Forward Price-to-Revenue Multiple DCTH (Delcath)|Market Cap to Expected Sales Ratio Y-mAbs Therapeutics, Inc.|Forward P/S Multiple AURA (Aura Biosciences Inc)|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CTOR|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|TARA: Forward Price to Sales|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio Aadi Bioscience|Price-to-Projected Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Projected Revenue|XBIT: Forward Price-to-Revenue Multiple|Forward Price to Sales CVM (cel-sci.com)|OSTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Forward P/S Multiple|Market Cap to Projected Revenue ANL (Adlai Nortye)|Price-to-Projected Revenue Ratio Veru Pharma (VERU)|Forward P/S Multiple Tempest Tx (TPST)|Price-to-Projected Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Projected Revenue Ratio|Mural Oncology - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple